Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02265913 · ClinicalTrials.gov registry record · Phase 3

Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis

A Phase 3 study, sponsored by Padagis.

Completed
Registry status
Phase 3
Development phase
4,076
Enrollment target

NCT02265913: Completed Phase 3 study, sponsored by Padagis.

NCT02265913 is a Phase 3 study that has completed, run by Padagis. The registered enrollment target is 4,076 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (428% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02265913, a Phase 3 study, has completed, sponsored by Padagis.

COMPLETED
Registry status
Phase 3
Development phase
4,076 participants
Enrollment target

Study Summary

To compare safety and efficacy of Perrigo's antiviral drug product compared to an FDA approved antiviral drug product in the treatment of cold sores.

Primary Outcome

Time to complete healing of lesions measured in hours from the time of first dosing

Interventions

  • DRUG Placebo cream
  • DRUG Acyclovir 5 percent (Perrigo)
  • DRUG Acyclovir 5 percent (Reference)

Trial Details

FieldValue
Enrollment Target 4,076 participants
Start Date 2014-10-06
Est. Completion 2017-11-21
Phase Phase 3
Padagis

17 total trials

What the finished NCT02265913 record still lists

NCT02265913 is an interventional study that assigns participants to a tested intervention. Its 4,076 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (428% higher).

The record links to 0 conditions, and to 3 interventions - of which Placebo cream is the first listed.

NCT02265913 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02265913 about?

NCT02265913 is a clinical study titled "Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis". To compare safety and efficacy of Perrigo's antiviral drug product compared to an FDA approved antiviral drug product in the treatment of cold sores.

What is the current status of trial NCT02265913?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,076 participants. The study started on 2014-10-06. Estimated completion is 2017-11-21.

What interventions are being tested in trial NCT02265913?

The interventions under investigation include: Placebo cream (DRUG), Acyclovir 5 percent (Perrigo) (DRUG), Acyclovir 5 percent (Reference) (DRUG).

Who is sponsoring clinical trial NCT02265913?

This trial is sponsored by Padagis, which has 17 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02265913's enrollment target sits among peer trials

4,076 61st of 2000 higher than 1,940 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03388606 · 4,100 participants

    Characterization and Treatment of Adolescent Depression

  • NCT00227253 · 4,000 participants

    Chromosome 18 Clinical Research Center

  • NCT00811148 · 4,000 participants

    Florida Center for Brain Tumor Research

  • NCT00897117 · 4,000 participants

    Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02265913, the US trial registry maintained by the National Library of Medicine. NCT02265913 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.